Compugen
A clinical-stage cancer immunotherapy company and a pioneer in computational target discovery
112 employees · est. 1993 · Israel
Nimbus Therapeutics
We develop breakthrough medicines for patients through precision small molecule design.
99 employees · est. 2009 · Boston, United States
Compugen is the older company (1993 vs 2009).
2 signals in the last 90 days
Side-by-Side Comparison
| Metric | Compugen | Nimbus Therapeutics |
|---|---|---|
| Founded | ||
| Founded | 1993 older | 2009 |
| Headquarters | ||
| Headquarters | Israel | Boston, United States |
| Employees | ||
| Employees | 112 | 99 |
| Industry | ||
| Industry | Analytics, Biotechnology, Computing | Biotechnology, Health Care, Health and Wellness |
| Funding Stage | ||
| Funding Stage | IPO | Private Equity |
| Total Funding | ||
| Total Funding | $126.00M | $637.00M |
| Funding Rounds | ||
| Funding Rounds | 6 | 9 |
| Services | ||
| Services | Drug Discovery, Clinical Trials, Therapeutic Development, AI/ML Application in Drug Research | Target Selection, Drug Discovery, Translational Medicine, Clinical Development, Development of Small Molecule Medicines |
| Target Customers | ||
| Target Customers | Pharmaceutical Companies, Biotech Investors, Healthcare Providers, Cancer Research Organizations, Oncology Researchers | Patients with Oncology Conditions, Patients with Immunological Disorders, Patients with Metabolic Indications, Biotechnology and Pharmaceutical Corporations, Healthcare Professionals |
| Taxonomy | ||
| Taxonomy | Cancer Immunotherapy, Computational Target Discovery, AI/ML Powered Discovery, Fc-reduced Antibodies, Bispecific Antibody Development, TIGIT Targeting Programs, PD-1/TIGIT Bispecific Antibodies, Immuno-Oncology, In Silico Prediction, Pharmaceutical Partnerships, Machine Learning Systems, Drug Development Pipeline, Therapeutic Discovery, In Silico Hypothesis-Driven Discovery, Experimental Validation | Precision Medicine, Small Molecule Design, Structure-based Drug Discovery, Computational Technologies, Machine Learning In Drug Development, Clinical-stage Therapeutics, Oncology, Immunology, Metabolic Diseases, Cancer Treatment, Autoimmune Conditions, HPK1 Inhibitor, WRN Program, Computational Chemistry |
| Website | ||
| Website | cgen.com | nimbustx.com |
About Compugen
Compugen is a clinical-stage company specializing in cancer immunotherapy, leveraging its AI/ML-powered computational discovery platform, Unigen™. Founded in 1993, this Israel-based firm is recognized for its pioneering role in computational target discovery. Compugen's innovative pipeline includes...
About Nimbus Therapeutics
Nimbus Therapeutics, founded in 2009, is a pioneering biotechnology company headquartered in the United States. The company is dedicated to developing breakthrough medicines through precision small molecule design, leveraging sophisticated computational technologies and machine learning-based predic...
We will tell you when either one moves
BounceWatch watches Compugen and Nimbus Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Compugen and Nimbus Therapeutics — by email.
Frequently Asked Questions
Compare Compugen with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Compugen on 22 Jun 2026, and Nimbus Therapeutics on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.